61203-50-7

Upstream product

• 20041-61-6 2-hydroxy-3-methoxy-4-nitrobenzaldehyde 
• 148-53-8 3-methoxy-2-hydroxybenzaldehyde 
• 7150-01-8 2-acetoxy-3-methoxybenzaldehyde 

Downstream Products

• 72517-19-2 2,3-dihydroxy-4-nitrobenzoic acid 
• 27864-01-3 4-chloro-2,3-dihydroxybenzoic acid 
• 183005-96-1 4-Ethoxycarbonylamino-2-ethoxycarbonyloxy-3-hydroxy-benzoic acid methyl ester 
• 183005-98-3 4-Amino-2,3-bis-ethoxycarbonyloxy-benzoic acid methyl ester 
• 183005-94-9 4-Ethoxycarbonylamino-2,3-dihydroxy-benzoic acid methyl ester 
• 183005-93-8 2,3-Dihydroxy-4-nitro-benzoic acid methyl ester 

Relevant academic research and scientific papers

Overcoming AlbD Protease Resistance and Improving Potency: Synthesis and Bioactivity of Antibacterial Albicidin Analogues with Amide Bond Isosteres

Albicidin is a potent antibacterial oligoaromatic peptide that is susceptible to the protease AlbD, a resistance factor. This potentially restricts the use of albicidin as a drug. To overcome this obstacle, we synthesized and evaluated six analogues with

Cystobactamid 507: Concise Synthesis, Mode of Action, and Optimization toward More Potent Antibiotics

Lack of new antibiotics and increasing antimicrobial resistance are among the main concerns of healthcare communities nowadays, and these concerns necessitate the search for novel antibacterial agents. Recently, we discovered the cystobactamids—a novel natural class of antibiotics with broad-spectrum antibacterial activity. In this work, we describe 1) a concise total synthesis of cystobactamid 507, 2) the identification of the bioactive conformation using noncovalently bonded rigid analogues, and 3) the first structure–activity relationship (SAR) study for cystobactamid 507 leading to new analogues with high metabolic stability, superior topoisomerase IIA inhibition, antibacterial activity and, importantly, stability toward the resistant factor AlbD. Deeper insight into the mode of action revealed that the cystobactamids employ DNA minor-groove binding as part of the drug–target interaction without showing significant intercalation. By designing a new analogue of cystobactamid 919-2, we finally demonstrated that these findings could be further exploited to obtain more potent hexapeptides against Gram-negative bacteria.

NOVEL CYSTOBACTAMIDES

The present invention provides cystobactamides of formula (I) and the use thereof the treatment or prophylaxis of bacterial infections.

CYSTOBACTAMIDES

The present invention provides cystobactamides of formula (I) and the use thereof for the treatment or prophylaxis of bacterial infections:

Synthesis and biological evaluation of cystobactamid 507: A bacterial topoisomerase inhibitor from Cystobacter sp.

Abstract The first total synthesis of cystobactamid 507, a member of a class of new natural products with strong inhibitory activity towards bacterial topoisomerases, is reported. Synthetic key challenges are the central tetrasubstitued arene and the low chemical reactivity of anilines and ortho-phenolic and isopropoxy-substituted benzoic acids. Biological evaluations demonstrate that cystobactamid 507 inhibits several Gram-positive pathogens but at significantly lower concentrations than described for the larger members of this natural product family.

Total Synthesis and Antimicrobial Activity of Chlorocatechelin A

Chlorocatechelin A (1) is a structurally unique microbial siderophore containing two units of 4-chloro-2,3-dihydroxybenzoic acid (CDB) and a characteristic acylguanidine structure. Purification from the microbe culture is not an easy task due to the labil

NOVEL BIOACTIVE SUBSTANCE

PROBLEM TO BE SOLVED: To provide a novel compound useful as an aminopeptidase A inhibitor. SOLUTION: This invention provides a compound represented by formula (I) or salt thereof, and a pharmaceutical composition comprising the same, wherein R1

AMINOQUINOLINE DERIVATIVES AS ANTIVIRAL AGENTS

Provided are compounds of Formula (I) and Formula (II) and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections mediated by a member of the Flaviviridae family of viruses such as hepatitis C virus (HCV).

Synthesis of 4-chloro-7-ethoxy-2(3H)-benzoxazolone-6-carboxylic acid

As a part of metabolic studies of mosapride (1), a potential gastroprokinetic agent, the synthesis of 4-chloro-7-ethoxy-2(3H)-benzoxazolone-6-carboxylic acid (7) as a derivative of 4-amino-5-chloro-2-ethoxy-3-hydroxybenzoic acid (6), which has served a benzoic acid part of the metabolites 4 and 5, is described. Treatment of methyl 3-amino-4-substituted amino-5-chloro-2-ethoxybenzoate derivatives 11a-c with sodium nitrate in acidic medium gave the benzotriazole derivatives 13x,y instead of the objective 3-hydroxy counterpart. The synthesis of 7 started from o-vanillin acetate (15) and proceeded through the intermediates 2-hydroxy-3-methoxy-4-nitrobenzaldehyde (18), methyl 4-amino-2,3-dihydroxybenzoate (23), and methyl 7-hydroxy-2(3H)-benzoxazolone-6-carboxylate (30). Compound 30 was alternatively prepared from 23 via methyl 4-ethoxycarbonylamino-2-ethoxycarbonyloxy-3-hydroxybenzoate (29), which is the product resulting from the migration of the ethoxycarbonyl group of methyl 4-amino-2,3-diethoxycarbonyloxybenzoate (27).